Clinical Trial Update: Immunogenicity and Safety of DCs in Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial assessing immunogenicity and safety of dendritic cells in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Fundación Salud de los Andes | Conditions: Breast Cancer Female | Phase 1, Phase 2 | Status: COMPLETED